Second Sight Medical Products develops, manufactures and markets implantable visual prosthetics that deliver artificial vision to blind individuals. Co. is developing the Orion® Visual Cortical Prosthesis System, an implanted cortical stimulation device which provides artificial vision to individuals who are blind due to a range of causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease and eye injury. Co.'s commercially approved product, the Argus® II Retinal Prosthesis System, treats outer retinal degenerations, such as retinitis pigmentosa, a hereditary disease that causes a progressive degeneration of the light-sensitive cells of the retina. We show 37 historical shares outstanding datapoints in our EYES shares outstanding history coverage, used to compute EYES market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing EYES market cap history over the course of time is important for investors
interested in comparing EYES's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of EYES versus a peer is one thing; comparing
EYES market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like EYES can fluctuate over the course of history.
With this page we aim to empower investors researching EYES by allowing them to research the EYES market cap history. |
Free EYES Email Alerts:
Video: The Importance of Market Cap
